Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 4990-5002

  Staedler, Davide ^a,b   Chapuis Bernasconi, Catherine ^a   Dehmlow, Henrietta ^c   Fischer, Holger ^c   Juillerat Jeanneret, Lucienne ^a   Aebi, Johannes D ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EPFL   (Switzerland)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [4 (4 HYDROXYPIPERIDINE 1 CARBONYL)CYCLOHEXYL]ETHYL]METHYLCARBAMIC ACID 4 CHLOROPHENYL ESTER; [4 [5 [ETHYL (2 HYDROXYETHYL)AMINO]PENT 1 YNYL] CYCLOHEXYL]METHYLCARBAMIC ACID 4 CHLOROPHENYL ESTER; ANTINEOPLASTIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; ISOMERASE INHIBITOR; LANOSTEROL SYNTHASE; OXIDOSQUALENE CYCLASE INHIBITOR; TRANS [2 [4 [[ETHYL (2 HYDROXYETHYL)AMINO]METHYL]CYCLOHEXYL] ETHYL]METHYLCARBAMIC ACID 4 TRIFLUOROMETHYLPHENYL ESTER CITRIC ACID; TRANS METHYL [4 [5 (METHYLPROPYLAMINO)PENT 1 YNYL]CYCLOHEXYL] CARBAMIC ACID 4 CHLORO PHENYL ESTER FUMARIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL SURVIVAL; CHOLESTEROL METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG SELECTIVITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; NEOVASCULARIZATION (PATHOLOGY); TUMOR GROWTH;

ALKYNES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS; BRAIN; CARBAMATES; CELL LINE, TUMOR; CELL PROLIFERATION; CRICETINAE; CYCLOHEXANES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENDOTHELIAL CELLS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRAMOLECULAR TRANSFERASES; MICROSOMES, LIVER; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862293720     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300256z     Document Type: Article

References (52)

1. Maxfield, F. R.; Tabas, I. Role of cholesterol and lipid organization in disease Nature 2005, 438, 612-621
2. Raposo, G.; Stenmark, H. Membranes and organelles Curr. Opin. Cell Biol. 2008, 20, 357-359
3. Nissen, S. E.; Tuzcu, E. M.; Schoenhagen, P.; Crowe, T.; Sasiela, W. J.; Tsai, J.; Orazem, J.; Magorien, R. D.; O'Shaughnessy, C.; Ganz, P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N. Engl. J. Med. 2005, 352, 29-38
4. Mills, E. J.; Rachlis, B.; Wu, P.; Devereaux, P. J.; Arora, P.; Perri, D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients J. Am. Coll. Cardiol. 2008, 52, 1769-1781
5. Demierre, M. F.; Higgins, P. D.; Gruber, S. B.; Hawk, E.; Lippman, S. M. Statins and cancer prevention Nat. Rev. Cancer 2005, 5, 930-942
6. Chan, K. K.; Oza, A. M.; Siu, L. L. The statins as anticancer agents Clin. Cancer Res. 2003, 9, 10-19
7. Cemeus, C.; Zhao, T. T.; Barrett, G. M.; Lorimer, I. A.; Dimitroulakos, J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status J. Neuro-Oncol. 2008, 90, 9-17
8. Guo, D.; Prins, R. M.; Dang, J.; Kuga, D.; Iwanami, A.; Soto, H.; Lin, K. Y.; Huang, T. T.; Akhavan, D.; Hock, M. B.; Zhu, S.; Kofman, A. A.; Bensinger, S. J.; Yong, W. H.; Vinters, H. V.; Horvath, S.; Watson, A. D.; Kuhn, J. G.; Robins, H. I.; Mehta, M. P.; Wen, P. Y.; DeAngelis, L. M.; Prados, M. D.; Mellinghoff, I. K.; Cloughesy, T. F.; Mischel, P. S. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy Sci. Signaling 2009, 2, ra82
9. van de Donk, N. W.; Kamphuis, M. M.; Lokhorst, H. M.; Bloem, A. C. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells Leukemia 2002, 16, 1362-1371
10. Graaf, M. R.; Richel, D. J.; van Noorden, C. J.; Guchelaar, H. J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer Cancer Treat. Rev. 2004, 30, 609-641
11. Vincent, L.; Chen, W.; Hong, L.; Mirshahi, F.; Mishal, Z.; Mirshahi-Khorassani, T.; Vannier, J. P.; Soria, J.; Soria, C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect FEBS Lett. 2001, 495, 159-166
12. Park, H. J.; Kong, D.; Iruela-Arispe, L.; Begley, U.; Tang, D.; Galper, J. B. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA Circ. Res. 2002, 91, 143-150
13. Weis, M.; Heeschen, C.; Glassford, A. J.; Cooke, J. P. Statins have biphasic effects on angiogenesis Circulation 2002, 105, 739-745
14. Dulak, J.; Jozkowicz, A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy Curr. Cancer Drug Targets 2005, 5, 579-594
15. Jakobisiak, M.; Golab, J. Statins can modulate effectiveness of antitumor therapeutic modalities Med. Res. Rev. 2010, 30, 102-135
16. Perchellet, J. P.; Perchellet, E. M.; Crow, K. R.; Buszek, K. R.; Brown, N.; Ellappan, S.; Gao, G.; Luo, D.; Minatoya, M.; Lushington, G. H. Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins Int. J. Mol. Med. 2009, 24, 633-643
17. Morand, O. H.; Aebi, J. D.; Dehmlow, H.; Ji, Y. H.; Gains, N.; Lengsfeld, H.; Himber, J. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin J. Lipid Res. 1997, 38, 373-390
18. Balliano, G.; Dehmlow, H.; Oliaro-Bosso, S.; Scaldaferri, M.; Taramino, S.; Viola, F.; Caron, G.; Aebi, J.; Ackermann, J. Oxidosqualene cyclase from Saccharomyces cerevisiae, Trypanosoma cruzi, Pneumocystis carinii and Arabidopsis thaliana expressed in yeast: a model for the development of novel antiparasitic agents Bioorg. Med. Chem. Lett. 2009, 19, 718-723
19. Dehmlow, H.; Aebi, J. D.; Jolidon, S.; Ji, Y. H.; von der Mark, E. M.; Himber, J.; Morand, O. H. Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors J. Med. Chem. 2003, 46, 3354-3370
20. Lenhart, A.; Reinert, D. J.; Aebi, J. D.; Dehmlow, H.; Morand, O. H.; Schulz, G. E. Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase J. Med. Chem. 2003, 46, 2083-2092
21. Rowe, A. H.; Argmann, C. A.; Edwards, J. Y.; Sawyez, C. G.; Morand, O. H.; Hegele, R. A.; Huff, M. W. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene: lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation Circ. Res. 2003, 93, 717-725
22. Telford, D. E.; Lipson, S. M.; Barrett, P. H.; Sutherland, B. G.; Edwards, J. Y.; Aebi, J. D.; Dehmlow, H.; Morand, O. H.; Huff, M. W. A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content Arterioscler., Thromb., Vasc. Biol. 2005, 25, 2608-2614
23. Gao, J.; Chu, X.; Qiu, Y.; Wu, L.; Qiao, Y.; Wu, J.; Li, D. Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway Chem. Commun. 2010, 46, 5340-5342
24. Mark, M.; Muller, P.; Maier, R.; Eisele, B. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells J. Lipid Res. 1996, 37, 148-158
25. Eisele, B.; Budzinski, R.; Müller, P.; Mark, M. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo J. Lipid Res. 1997, 38, 564-575
26. Dollis, D.; Schuber, F. Effects of 2,3-oxidosqualene-lanosterol cyclase inhibitor, 2,3:22,23-dioxidosqualene and 24,25-epoxycholesterol on the regulation of cholesterol biosynthesis in human hepatoma cell line Hep-G2 Biochem. Pharmacol. 1994, 48, 49-57
27. Peffley, D. M.; Gayen, A. K.; Morand, O. H. Down-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels and synthesis in syrian hamster C100 cells by the oxidosqualene cyclase inhibitor [4′-(6-allyl-ethyl-amino-hexyloxy)-2′-fluoro-phenyl]-(4-bromophenyl) -methanone (RO0488071): comparison to simvastatin Biochem. Pharmacol. 1998, 56, 439-449
28. Gardner, R. G.; Shan, H.; Matsuda, S. P. T.; Hampton, R. Y. An oxysterol-derived positive signal for 3-hydroxy-3-methylglutaryl-CoA reductase degradation in yeast J. Biol. Chem. 2001, 276, 8681-8694
29. Dehmlow, H.; Ackermann, J.; Aebi, J.; Blum-Kaelin, D.; Chucholowski, A.; Coassolo, P.; Hartman, P.; Kansy, M.; Maerki, H. P.; Morand, O.; Von der Mark, E.; Panday, N.; Ruf, A.; Thoma, R.; Schulz-Gasch, T. Oxidosqualene cyclase (OSC) inhibitors for the treatment of dyslipidemia Chimia 2005, 59, 72-76
30. Jolidon, S.; Polak-Wyss, A.; Hartman, P. G.; Guerry, P. 2,3-Oxidosqualenelanosterol Cyclase: An Attractive Target for Antifungal Drug Design. In Recent Advances in the Chemistry of Anti-Infective Agents; Bentley, P. H.; Ponsford, R, Eds.; Bookcraft Ltd.: Bath, U.K., 1993; pp 223-233.
31. Thoma, R.; Schulz-Gasch, T.; D'Arcy, B.; Benz, J.; Aebi, J.; Dehmlow, H.; Hennig, M.; Stihle, M.; Ruf, A. Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase Nature 2004, 432, 118-122
32. Corey, E. J.; Fuchs, P. L. Synthetic method for conversion of formyl groups into ethynyl groups Tetrahedron Lett. 1972, 36, 3769-3772
33. Li, P.; Yamamoto, H. Amino acid salt catalyzed intramolecular Robinson annulation Chem. Commun. 2009, 36, 5412-5414
34. Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. A greatly improved procedure for ruthenium tetroxide catalyzed oxidations of organic compounds J. Org. Chem. 1981, 46, 3936-3938
35. Brusselmans, K.; Timmermans, L.; Van de Sande, T.; Van Veldhoven, P. P.; Guan, G.; Schechter, I.; Claessens, F.; Verhoeven, G.; Swinnen, J. V. Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation J. Biol. Chem. 2007, 282, 18777-18785
36. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharm. Rev. 2006, 58, 621-681
37. Lee, J. J.; Kong, M.; Ayers, G. D.; Lotan, R. Interaction index and different methods for determining drug interaction in combination therapy J. Biopharm. Stat. 2007, 17, 461-480
38. Wuitschik, G.; Carreira, E. M.; Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.; Rogers-Evans, M.; Muller, K. Oxetanes in drug discovery: structural and synthetic insights J. Med. Chem. 2010, 53, 3227-3246
39. Kansy, M.; Senner, F.; Gubernator, K. Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes J. Med. Chem. 1998, 41, 1007-1010
40. Bjorkhem, I.; Meaney, S. Brain cholesterol: long secret life behind a barrier Arterioscler., Thromb., Vasc. Biol. 2004, 24, 806-815
41. Dietschy, J. M.; Turley, S. D. Cholesterol metabolism in the central nervous system during early development and in the mature animal J. Lipid Res. 2004, 45, 1375-1397
42. Natali, F.; Siculella, L.; Salvati, S.; Gnoni, G. V. Oleic acid is a potent inhibitor of fatty acid and cholesterol synthesis in C6 glioma cells J. Lipid Res. 2007, 48, 1966-1975
43. Prasanna, P.; Thibault, A.; Liu, L.; Samid, D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells J. Neurochem. 1996, 66, 710-716
44. Brown, R. C.; Cascio, C.; Papadopoulos, V. Pathways of neurosteroid biosynthesis in cell lines from human brain: regulation of dehydroepiandrosterone formation by oxidative stress and beta-amyloid peptide J. Neurochem. 2000, 74, 847-859
45. Bababeygy, S. R.; Polevaya, N. V.; Youssef, S.; Sun, A.; Xiong, A.; Prugpichailers, T.; Veeravagu, A.; Hou, L. C.; Steinman, L.; Tse, V. HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model Anticancer Res. 2009, 29, 4901-4908
46. Bouterfa, H. L.; Sattelmeyer, V.; Czub, S.; Vordermark, D.; Roosen, K.; Tonn, J. C. Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells Anticancer Res. 2000, 20, 2761-2771
47. Chan, D. Y. L.; Chen, G. G.; Poon, W. S.; Liu, P. C. Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis J. Neuro-Oncol. 2008, 86, 273-283
48. Jiang, Z.; Zheng, X.; Lytle, R. A.; Higashikubo, R.; Rich, K. M. Lovastatin-induced up-regulation of the BH3-only protein, Bim, and cell death in glioblastoma cells J. Neurochem. 2004, 89, 168-178
49. Schmidt, F.; Groscurth, P.; Kermer, M.; Dichgans, J.; Weller, M. Lovastatin and phenylacetate induce apoptosis, but not differentiation in human malignant glioma cells Acta Neuropathol. 2001, 101, 217-224
50. Tapia-Perez, J. H.; Kirches, E.; Mawrin, C.; Firsching, R.; Schneider, T. Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells Cancer Chemother. Pharmacol. 2011, 67, 1193-1201
51. Larner, J.; Jane, J.; Laws, E.; Packer, R.; Myers, C.; Shaffrey, M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme Am. J. Clin. Oncol. 1998, 21, 579-583
52. Berger, Y.; Dehmlow, H.; Blum-Kaelin, D.; Kitas, E. A.; Löffler, B. M.; Aebi, J. D.; Juillerat-Jeanneret, L. Endothelin-converting-enzyme-1 inhibition and growth of human glioblastoma cells J. Med. Chem. 2005, 48, 483-498